First Trust Advisors LP Has $77.13 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

First Trust Advisors LP raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 14.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 327,782 shares of the biopharmaceutical company's stock after acquiring an additional 42,211 shares during the period. First Trust Advisors LP owned about 0.25% of Alnylam Pharmaceuticals worth $77,130,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jennison Associates LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $61,160,000. Strategic Financial Concepts LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $41,529,000. Truist Financial Corp lifted its holdings in shares of Alnylam Pharmaceuticals by 136.6% in the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock valued at $1,035,000 after purchasing an additional 2,539 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after purchasing an additional 8,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Alnylam Pharmaceuticals by 13.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock valued at $4,687,000 after purchasing an additional 2,285 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CMO Pushkal Garg sold 52,592 shares of the company's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares of the company's stock, valued at $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the company's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares of the company's stock, valued at $20,802,989.42. This represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 59,984 shares of company stock valued at $16,864,347. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded up $8.95 during midday trading on Friday, reaching $251.56. 835,531 shares of the company were exchanged, compared to its average volume of 879,273. The business has a 50-day moving average price of $247.37 and a two-hundred day moving average price of $255.84. The firm has a market capitalization of $32.72 billion, a price-to-earnings ratio of -115.93 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a one year low of $143.50 and a one year high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ALNY. StockNews.com upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, April 22nd. Citigroup boosted their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a report on Friday, March 21st. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a report on Friday, March 21st. Scotiabank boosted their price target on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a report on Monday, March 31st. Finally, Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $315.58.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.